Standardizing wound treatment procedures for advanced technologies.
New drugs and tissue replacements are currently being approved and integrated into treatment regimens for chronic wounds. This article focuses on a standardized procedure for the use of specific growth factor, a recombinant human platelet-derived growth factor (rhPDGF-BB) manufactured for topical administration. The recommendations made in this article may not reflect product recommendations made by the manufacturer of the drug. Clinicians must be able to support any off-label indication for use of a product.
Mulder
Gerit D
GD
University of California San Diego Medical Center, Regional Burn Center/Wound Treatment and Research Center, 200 W Arbor Dr 8896, San Diego, CA 92103-8896, USA.
D000287:Administration, Topical; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011032:Podiatry / Q000592:standards; D017410:Practice Guidelines as Topic; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology; D014947:Wounds and Injuries / Q000188:drug therapy*
D010982:Platelet-Derived Growth Factor